logo-loader

Abcam forecasts double digit revenue growth for full-year as it sees product growth across the board

Published: 20:59 12 Jul 2018 AEST

Antibodies
Revenue from custom products and licensing also grew by 18% during the year

Abcam PLC (LON:ABC) said it expects double-digit growth in its full-year results following strong income growth across all of its product categories.

The AIM-listed antibody supplier said it expects revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10% underpinning the rise after all product categories continued to grow ahead of its market.

READ: Abcam raises revenue guidance after Roche deal

The firm added that revenue from custom products and licensing, which accounted for around 7% of total revenue, also grew by 18% during the year.

Abcam also said it expected margins to be in line with the previous year's figure of 70.1%, while margins for adjusted earnings before interest, taxes, depreciation and amortisation were forecast to be in line with expectations.

In a note to clients, analysts at City broker Numis upped their target price for the firm to 1,380p from 1,316p, citing that the strong growth forecasts could “indicate the emergence of a new fourth double-digit growth engine in the business”.

In lunchtime trading Thursday, Abcam shares were down 4.8% at 1,322p.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 15 minutes ago